Voya Investment Management LLC Has $1.79 Million Position in LeMaitre Vascular, Inc. $LMAT

Key Points

• Voya Investment Management LLC reduced its stake in LeMaitre Vascular, Inc. by 52.7%, selling 23,752 shares to hold 21,291 shares worth approximately $1.79 million.
• LeMaitre Vascular reported a quarterly EPS of $0.60, exceeding estimates, with revenue of $63.15 million—up 15% year-over-year.
• The company recently announced a quarterly dividend of $0.20, representing an annualized yield of 0.9% and a payout ratio of 38.83%.

Voya Investment Management LLC cut its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 52.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,291 shares of the medical instruments supplier's stock after selling 23,752 shares during the quarter. Voya Investment Management LLC owned about 0.09% of LeMaitre Vascular worth $1,786,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Opal Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular during the 1st quarter valued at about $26,000. NBC Securities Inc. bought a new position in LeMaitre Vascular in the 1st quarter valued at $36,000. Geneos Wealth Management Inc. grew its position in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after acquiring an additional 398 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of LeMaitre Vascular in the 1st quarter worth $50,000. Finally, US Bancorp DE lifted its stake in shares of LeMaitre Vascular by 36.0% during the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 368 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the transaction, the chief executive officer directly owned 1,727,003 shares in the company, valued at approximately $161,492,050.53. The trade was a 5.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John A. Roush sold 6,561 shares of the company's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the sale, the director owned 2,916 shares of the company's stock, valued at $269,875.80. This represents a 69.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 120,815 shares of company stock worth $11,280,206 over the last three months. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Trading Up 0.0%

Shares of LeMaitre Vascular stock traded up $0.04 during trading hours on Monday, reaching $92.29. 171,259 shares of the company's stock were exchanged, compared to its average volume of 183,602. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of 44.80, a price-to-earnings-growth ratio of 2.37 and a beta of 0.79. The company has a fifty day moving average of $90.69 and a 200-day moving average of $86.05. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same period in the prior year, the firm earned $0.52 EPS. The firm's quarterly revenue was up 15.0% compared to the same quarter last year. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, August 21st. This represents a $0.80 annualized dividend and a yield of 0.9%. LeMaitre Vascular's payout ratio is presently 38.83%.

Analyst Upgrades and Downgrades

LMAT has been the subject of several research analyst reports. Cantor Fitzgerald raised their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Barrington Research upgraded LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $97.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.